Journal
DRUG DESIGN DEVELOPMENT AND THERAPY
Volume 12, Issue -, Pages 1977-1983Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S167926
Keywords
PP13; ELISA; PK; eNOS; prostaglandin; preeclampsia
Categories
Funding
- European Union through the ASPRE project [601852]
- Hananjaehf
- Icelandic Research Fund (Rannis) [163403-052]
Ask authors/readers for more resources
Introduction: Human placental protein 13 (PP13) is a galectin predominantly expressed by the placenta. Low serum concentrations of PP13 in early pregnancy indicate a higher risk of developing preeclampsia. Methods: The pharmacokinetic disposition and bioavailability of PP13 were determined by single intravenous and subcutaneous administration to 12 healthy New Zealand White rabbits. The serum pharmacokinetic values were determined by enzyme-linked immunosorbent assay, and are best described by a two-compartment model. Results: Both volume of distribution and the area under the curve were dose dependent for the intravenous group (p < 0.01). PP13 elimination half-life was also found to be different between the groups (p < 0.01). The bioavailability of PP13 following subcutaneous administration was found to be 57%. Conclusion: This study shows that the concentration of total PP13 released into the maternal circulation during pregnancy might be much higher than previously estimated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available